Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pharmaceutical R&D is emerging from a turbulent couple of years, as the COVID-19 pandemic threatened to blow it off course, forcing it to urgently respond to a global health crisis, whilst simultaneously changing many of the ways in which it conducted clinical development. As the world begins to get back to normal, what has been the overall effect on the drug pipeline?
This webinar will examine the question and will be based around the Citeline Pharma R&D Annual Review, now in its thirtieth year, which looks at trends both short- and long-term in drug development. Ian Lloyd, Senior Director of Citeline’s Pharmaprojects database, the report’s author will present analyses of leading companies, diseases, mechanisms and targets, and drug types. The review includes exclusive APAC-centred content, with a particular focus on the explosion of novel pharma R&D which is occurring in China.
This year being the 30th anniversary, we are inviting key opinion leaders from across the APAC and EMEAI regions to discuss the drug development and pipeline in 2022. This roundtable discussion will be hosted by Ian Haydock, Editor-in-Chief, Pharma, APAC, Scrip Group who spends years writing about Pharma R&D and drug development articles. Come join us as this webinar promises to provide unique insight into the state of global and regional R&D in 2022.
Key topics that will be discussed
R&D Competitive Intelligence Lead
NIBR/GDD Competitive & Business Insights
Novartis Pharma AG
Andrew is responsible for R&D competitive intelligence at Novartis, providing data-driven analysis and insights across the Novartis portfolio to aid strategic decision making. Our focus is broad, from supporting early exploratory scientific research, right through to late stage product development.
A particular focus is the support of portfolio strategy, which requires a holistic view of our internal R&D activities, as well as an understanding of industry trends and innovation.
Andrew has been working at Novartis for 18 years, initially in the UK, before moving to Switzerland in 2006. For the last 3 years, Andrew has served as the Chairperson for the Pharma CI Europe Conference, and actively participates in expert CI panels and round table discussions, embracing all aspects of competitive intelligence.
Prior to joining Novartis, Andrew worked as a Senior Patent Analyst at Thomson Reuters
He obtained a PhD in synthetic organic chemistry from the University of East Anglia, UK.
Senior Director, Pharmaprojects & Data Integration
Informa Pharma Intelligence
Ian Lloyd is the Senior Director of Pharmaprojects and Data Integration, overseeing the content and analyst services for our drug development solution. He supports clients in their drug pipeline data requirements and drug pipeline inquiries, providing insight into the best search strategies to answer their drug research and development business questions.
Head of R&D Strategy & Portfolio Management, Global R&D Center, Shanghai Fosun Pharma, China
APAC Regional Head Executive Vice President of Clinical Development
President & Head, Nonclinical Research & Development
Zydus Life
Dr. Mukul Jain is working with Zydus Lifesciences Ltd.as President at Zydus Research Centre,Ahmedabad and is responsible for new drug discovery & development. He was the key person responsible for discovery & development of Saroglitazar and Desidustat, the first NCEs that came from an Indian Pharmaceutical Company and got approved for use in human patients. Besides Saroglitazar and Desidustat, he has contributed to discovery & development of 16 other New Chemical Entities that crossed IND stage of development. Besides NCEs, his group has completed nonclinical safety assessment of 15 biologicals and 14 vaccines of Zydus Cadila. Dr. Jain obtained his B.Pharm, M.Pharm & PhD degrees from Dept. of Pharmaceutical Sciences, Nagpur University.
He has also completed an Executive Management course from IIM, Ahmedabad and a Post-doc at University of Florida, Gainesville, USA. He has over 31years’ professional experience, starting with Nagpur University followed by Wockhardt, Ranbaxy, Univ. of Florida and NIPER-Mohali before joining Zydus group in 2000. He has contributed to 172 full-length research papers, 4 book chapters and over 77 patents. He is a Member of the Governing Board of NIPER, Ahmedabad; Research Advisory Council Member of CSIR-IITR and Gujarat Biotechnology Research Center; Editorial Advisory Board Member of 'American Chemical Society’s ‘Medicinal Chemistry Letters’; and also a member of various International Scientific Societies including ADA, EASD, AACR, AAAS, AASLD, EASL, IPS, ASPET and ACS.
Editor-in-chief, APAC
Informa Pharma Intelligence
Ian oversees content for the Asia-Pacific area, including in the commercial and policy/regulation areas, with a particular interest in company and pricing topics. He has been covering the region for more than 20 years as a writer and editor in the pharma sector.
Ian first moved to Japan in the 1990s and has covered a broad range of pharma industry topics, both across this market and the rest of Asia, including corporate, R&D, pricing and policy developments. After a stint as a Tokyo-based Japan and Asia editor for Scrip, he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet) in 2014, and is a recipient of multiple Informa internal awards. He has a long personal and professional background in Asia, having grown up in Hong Kong, and follows regional regulatory harmonization and trade initiatives with interest. Ian lives in Tokyo with his wife and two sons.
